Type 1 diabetes and cardiovascular disease

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Schnell, Oliver ^a   Cappuccio, Francesco ^b   Genovese, Stefano ^c   Standl, Eberhard ^a   Valensi, Paul ^d   Ceriello, Antonio ^e  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c IRCCS MULTIMEDICA   (Italy)

^d HÔPITAL JEAN VERDIER   (France)

^e HOSPITAL CLÍNIC   (Spain)

Author keywords

Cardiovascular disease; Type 1 diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; C PEPTIDE; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; EXENDIN 4; FIBRINOGEN; GLUCAGON LIKE PEPTIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; THIAZIDE DIURETIC AGENT; TUMOR NECROSIS FACTOR ALPHA; ANTIHYPERTENSIVE AGENT; GLUCAGON LIKE PEPTIDE 1; INSULIN; PEPTIDE; PYRAZINE DERIVATIVE; SITAGLIPTIN; TRIAZOLE DERIVATIVE; VENOM;

ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; AUGMENTATION INDEX; AUTONOMIC NEUROPATHY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY CALCIFICATION; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DYSLIPIDEMIA; ELECTRON BEAM TOMOGRAPHY; ENDOTHELIAL DYSFUNCTION; GLYCEMIC CONTROL; HEART MUSCLE METABOLISM; HUMAN; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPOGLYCEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; MICROALBUMINURIA; MITOCHONDRIAL RESPIRATION; MULTIDETECTOR COMPUTED TOMOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PULSE WAVE; REVIEW; SYMPATHETIC INNERVATION; SYSTOLIC BLOOD PRESSURE; AGONISTS; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DRUG COMBINATION; KINESIOTHERAPY; METABOLISM; PHYSIOLOGY;

ANTIHYPERTENSIVE AGENTS; AUTONOMIC NERVOUS SYSTEM DISEASES; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES; DRUG THERAPY, COMBINATION; EXERCISE THERAPY; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; OXIDATIVE STRESS; PEPTIDES; PYRAZINES; TRIAZOLES; VENOMS;

EID: 84886212399     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-156     Document Type: Review

References (125)

1. Preis SR, Hwang SJ, Coady S, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009, 119:1728-1735. 10.1161/CIRCULATIONAHA.108.829176, 2789419, 19307472.
2. Nishimura R, LaPorte RE, Dorman JS, et al. Mortality trends in type 1 diabetes. The Allegheny County (Pennsylvania) Registry 1965-1999. Diabetes Care 2001, 24:823-827. 10.2337/diacare.24.5.823, 11347737.
3. Miller RG, Secrest AM, Sharma RK, Songer TJ, Orchard TJ. Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications study cohort. Diabetes 2012, 61:2987-2992. 10.2337/db11-1625, 3478551, 22851572.
4. Schnell O, Standl E. Diabetes and cardiovascular disease. Current status of trials. Clin Res Cardiol Suppl 2010, (5):27-34.
5. Koivisto VA, Stevens LK, Mattock M, et al. Cardiovascular disease and its risk factors in IDDM in Europe, EURODIAB IDDM Complications Study Group. Diabetes Care 1996, 19:689-697. 10.2337/diacare.19.7.689, 8799621.
6. Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care 2008, 31:714-719. 10.2337/dc07-2124, 18083789.
7. Standl E, Balletshofer B, Dahl B, et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 1996, 39:1540-1545. 10.1007/s001250050612, 8960840.
8. Shankar A, Klein R, Klein BE, Moss SE. Association between glycosylated hemoglobin level and cardiovascular and all-cause mortality in type 1 diabetes. Am J Epidemiol 2007, 166:393-402. 10.1093/aje/kwm096, 17526864.
9. Morimoto A, Onda Y, Nishimura R, et al. Cause-specific mortality trends in a nationwide population-based cohort of childhood-onset type 1 diabetes in Japan during 35 years of follow-up: the DERI Mortality Study. Diabetologia 2013, 56:2171-2175. 10.1007/s00125-013-3001-2, 23903695.
10. Constantino MI, Molyneaux L, Limacher-Gisler F, et al. Long-Term Complications and Mortality in Young-Onset Diabetes: Type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care 2013,
11. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007, 28:88-136.
12. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 2003, 26:1589-1596. 10.2337/diacare.26.5.1589, 12716823.
13. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat?. Diabetes 2005, 54:1-7. 10.2337/diabetes.54.1.1, 15616004.
14. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010, 33:1389-1394. 10.2337/dc09-2082, 2875462, 20508232.
15. Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res 2010, 7:260-273. 10.1177/1479164110383723, 20847109.
16. Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 2011, doi: 10.1002/dmrr.1239.
17. Witte DR, Tesfaye S, Chaturvedi N, et al. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia 2005, 48:164-171. 10.1007/s00125-004-1617-y, 15619072.
18. The DCCT Research Group The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998, 41:416-423. 10.1007/s001250050924, 2635092, 9562345, The DCCT Research Group.
19. Pop-Busui R, Low PA, Waberski BH, et al. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009, 119:2886-2893. 10.1161/CIRCULATIONAHA.108.837369, 2757005, 19470886.
20. Astrup AS, Tarnow L, Rossing P, et al. Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2006, 29:334-339. 10.2337/diacare.29.02.06.dc05-1242, 16443883.
21. Ayad F, Belhadj M, Paries J, Attali JR, Valensi P. Association between cardiac autonomic neuropathy and hypertension and its potential influence on diabetic complications. Diabet Med 2010, 27:804-811. 10.1111/j.1464-5491.2010.03027.x, 20636962.
22. Prince CT, Secrest AM, Mackey RH, et al. Cardiovascular autonomic neuropathy, HDL cholesterol, and smoking correlate with arterial stiffness markers determined 18 years later in type 1 diabetes. Diabetes Care 2010, 33:652-657. 10.2337/dc09-1936, 2827525, 20040653.
23. Standl E, Schnell O. A new look at the heart in diabetes mellitus: from ailing to failing. Diabetologia 2000, 43:1455-1469. 10.1007/s001250051556, 11151754.
24. Schnell O. Cardiac sympathetic innervation and blood flow regulation of the diabetic heart. Diabetes Metab Res Rev 2001, 17:243-245. 10.1002/dmrr.220, 11544608.
25. Schnell O, Kirsch CM, Stemplinger J, Haslbeck M, Standl E. Scintigraphic evidence for cardiac sympathetic dysinnervation in long-term IDDM patients with and without ECG-based autonomic neuropathy. Diabetologia 1995, 38:1345-1352. 10.1007/BF00401768, 8582545.
26. Hattori N, Tamaki N, Hayashi T, et al. Regional abnormality of iodine-123-MIBG in diabetic hearts. J Nucl Med 1996, 37:1985-1990.
27. Schnell O, Muhr D, Weiss M, et al. Reduced myocardial 123I-metaiodobenzylguanidine uptake in newly diagnosed IDDM patients. Diabetes 1996, 45:801-805. 10.2337/diab.45.6.801, 8635656.
28. Munch G, Ziegler S, Nguyen N, et al. Scintigraphic evaluation of cardiac autonomic innervation. J Nucl Cardiol 1996, 3:265-277. 10.1016/S1071-3581(96)90040-9, 8805746.
29. Schnell O, Muhr D, Dresel S, et al. Partial restoration of scintigraphically assessed cardiac sympathetic denervation in newly diagnosed patients with insulin-dependent (type 1) diabetes mellitus at one-year follow-up. Diabet Med 1997, 14:57-62. 10.1002/(SICI)1096-9136(199701)14:1<57::AID-DIA297>3.0.CO;2-7, 9017355.
30. Meyer C, Schwaiger M. Myocardial blood flow and glucose metabolism in diabetes mellitus. Am J Cardiol 1997, 80:94A-101A. 10.1016/S0002-9149(97)00463-3, 9293961.
31. Stevens MJ, Dayanikli F, Raffel DM, et al. Scintigraphic assessment of regionalized defects in myocardial sympathetic innervation and blood flow regulation in diabetic patients with autonomic neuropathy. J Am Coll Cardiol 1998, 31:1575-1584. 10.1016/S0735-1097(98)00128-4, 9626837.
32. Vom-Dahl J, Herman WH, Hicks RJ, et al. Myocardial glucose uptake in patients with insulin-dependent diabetes mellitus assessed quantitatively by dynamic positron emission tomography. Circulation 1993, 88:395-404. 10.1161/01.CIR.88.2.395, 8339403.
33. Hattori N, Tamaki N, Kudoh T, et al. Abnormality of myocardial oxidative metabolism in noninsulin-dependent diabetes mellitus. J Nucl Med 1998, 39:1835-1840.
34. Pop-Busui R. What do we know and we do not know about cardiovascular autonomic neuropathy in diabetes. J Cardiovasc Transl Res 2012, 5:463-478. 10.1007/s12265-012-9367-6, 3634565, 22644723.
35. Pop-Busui R, Kirkwood I, Schmid H, et al. Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. J Am Coll Cardiol 2004, 44:2368-2374. 10.1016/j.jacc.2004.09.033, 15607400.
36. Pfeifer MA, Schumer MP. Clinical trials of diabetic neuropathy: past, present, and future. Diabetes 1995, 44:1355-1361.
37. Allman KC, Stevens MJ, Wieland DM, et al. Noninvasive assessment of cardiac diabetic neuropathy by carbon-11 hydroxyephedrine and positron emission tomography. J Am Coll Cardiol 1993, 22:1425-1432. 10.1016/0735-1097(93)90553-D, 8227801.
38. Stevens MJ, Raffel DM, Allman KC, et al. Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation 1998, 98:961-968. 10.1161/01.CIR.98.10.961, 9737515.
39. Schnell O, Muhr D, Dresel S, et al. Autoantibodies against sympathetic ganglia and evidence of cardiac sympathetic dysinnervation in newly diagnosed and long-term IDDM patients. Diabetologia 1996, 39:970-975. 10.1007/BF00403917, 8858220.
40. Muhr D, Mollenhauer U, Ziegler AG, et al. Autoantibodies to sympathetic ganglia, GAD, or tyrosine phosphatase in long-term IDDM with and without ECG-based cardiac autonomic neuropathy. Diabetes Care 1997, 20:1009-1012. 10.2337/diacare.20.6.1009, 9167116.
41. Muhr-Becker D, Ziegler AG, Druschky A, et al. Evidence for specific autoimmunity against sympathetic and parasympathetic nervous tissues in Type 1 diabetes mellitus and the relation to cardiac autonomic dysfunction. Diabet Med 1998, 15:467-472. 10.1002/(SICI)1096-9136(199806)15:6<467::AID-DIA621>3.0.CO;2-Q, 9632120.
42. Ejskjaer N, Arif S, Dodds W, et al. Prevalence of autoantibodies to autonomic nervous tissue structures in Type 1 diabetes mellitus. Diabet Med 1999, 16:544-549. 10.1046/j.1464-5491.1999.00092.x, 10445828.
43. Rabinowe SL, Brown FM, Watts M, Kadrofske MM, Vinik AI. Anti-sympathetic ganglia antibodies and postural blood pressure in IDDM subjects of varying duration and patients at high risk of developing IDDM. Diabetes Care 1989, 12:1-6. 10.2337/diacare.12.1.1, 2653745.
44. Sundkvist G, Lind P, Bergstrom B, Lilja B, Rabinowe SL. Autonomic nerve antibodies and autonomic nerve function in type 1 and type 2 diabetic patients. J Intern Med 1991, 229:505-510. 10.1111/j.1365-2796.1991.tb00386.x, 2045757.
45. Zanone MM, Peakman M, Purewal T, Watkins PJ, Vergani D. Autoantibodies to nervous tissue structures are associated with autonomic neuropathy in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993, 36:564-569. 10.1007/BF02743275, 8335180.
46. Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care 2011, 34(Suppl 2):S132-S137. 3632150, 21525444.
47. Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor?. Diabetes Metab Res Rev 2008, 24:353-363. 10.1002/dmrr.865, 18461635.
48. Sommerfield AJ, Wilkinson IB, Webb DJ, Frier BM. Vessel wall stiffness in type 1 diabetes and the central hemodynamic effects of acute hypoglycemia. Am J Physiol Endocrinol Metab 2007, 293:E1274-E1279. 10.1152/ajpendo.00114.2007, 17726149.
49. Robinson RT, Harris ND, Ireland RH, et al. Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia. Diabetes 2003, 52:1469-1474. 10.2337/diabetes.52.6.1469, 12765959.
50. Koivikko ML, Karsikas M, Salmela PI, et al. Effects of controlled hypoglycaemia on cardiac repolarisation in patients with type 1 diabetes. Diabetologia 2008, 51:426-435. 10.1007/s00125-007-0902-y, 18097646.
51. Tattersall RB, Gill GV. Unexplained deaths of type 1 diabetic patients. Diabet Med 1991, 8:49-58. 10.1111/j.1464-5491.1991.tb01516.x, 1826245.
52. Campbell I. Dead in bed syndrome: a new manifestation of nocturnal hypoglycaemia?. Diabet Med 1991, 8:3-4. 10.1111/j.1464-5491.1991.tb01507.x, 1826241.
53. Sartor G, Dahlquist G. Short-term mortality in childhood onset insulin-dependent diabetes mellitus: a high frequency of unexpected deaths in bed. Diabet Med 1995, 12:607-611. 10.1111/j.1464-5491.1995.tb00550.x, 7554783.
54. Dahlquist G, Kallen B. Mortality in childhood-onset type 1 diabetes: a population-based study. Diabetes Care 2005, 28:2384-2387. 10.2337/diacare.28.10.2384, 16186267.
55. Skrivarhaug T, Bangstad HJ, Stene LC, et al. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia 2006, 49:298-305. 10.1007/s00125-005-0082-6, 16365724.
56. Tu E, Twigg SM, Duflou J, Semsarian C. Causes of death in young Australians with type 1 diabetes: a review of coronial postmortem examinations. Med J Aust 2008, 188:699-702.
57. Barkai L, Gurieva I, Stirban A, et al. Microvascular complications in children and adolescents with type 1 diabetes. Diabetes Metab Heart 2012, 21:309-315.
58. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653. 2637991, 16371630.
59. Orchard TJ, Olson JC, Erbey JR, et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2003, 26:1374-1379. 10.2337/diacare.26.5.1374, 12716791.
60. The DCCT Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977-986. The DCCT Research Group.
61. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003, 290:2159-2167. 2622725, 14570951.
62. Monti MC, Lonsdale JT, Montomoli C, et al. Familial risk factors for microvascular complications and differential male-female risk in a large cohort of American families with type 1 diabetes. J Clin Endocrinol Metab 2007, 92:4650-4655. 10.1210/jc.2007-1185, 17878250.
63. Conway B, Costacou T, Orchard T. Is glycaemia or insulin dose the stronger risk factor for coronary artery disease in type 1 diabetes?. Diab Vasc Dis Res 2009, 6:223-230. 10.1177/1479164109336041, 2865431, 20368215.
64. Dorchy H, Claes C, Verougstraete C. Risk factors of developing proliferative retinopathy in type 1 diabetic patients: role of BMI. Diabetes Care 2002, 25:798-799. 10.2337/diacare.25.4.798, 11919142.
65. De Block CE, De Leeuw IH, Van Gaal LF. Impact of overweight on chronic microvascular complications in type 1 diabetic patients. Diabetes Care 2005, 28:1649-1655. 10.2337/diacare.28.7.1649, 15983315.
66. Stone ML, Craig ME, Chan AK, et al. Natural history and risk factors for microalbuminuria in adolescents with type 1 diabetes: a longitudinal study. Diabetes Care 2006, 29:2072-2077. 10.2337/dc06-0239, 16936155.
67. Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996, 39:1377-1384. 10.1007/s001250050586, 8933008.
68. Chase HP, Garg SK, Marshall G, et al. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA 1991, 265:614-617. 10.1001/jama.1991.03460050068022, 1987411.
69. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA 2007, 298:902-916. 10.1001/jama.298.8.902, 17712074.
70. Tuomilehto J, Borch-Johnsen K, Molarius A, et al. Incidence of cardiovascular disease in Type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia 1998, 41:784-790. 10.1007/s001250050988, 9686919.
71. Turkbey EB, Backlund JY, Genuth S, et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation 2011, 124:1737-1746. 10.1161/CIRCULATIONAHA.111.022327, 3215589, 21947298.
72. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013, Epub ahead of print.
73. Viberti GC, Keen H, Wiseman MJ. Raised arterial pressure in parents of proteinuric insulin dependent diabetics. Br Med J (Clin Res Ed) 1987, 295:515-517. 10.1136/bmj.295.6597.515, 1247425, 3117203.
74. Krolewski AS, Canessa M, Warram JH, et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med 1988, 318:140-145. 10.1056/NEJM198801213180303, 3336401.
75. Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002, 347:797-805. 10.1056/NEJMoa013410, 12226150.
76. de Boer IH, Kestenbaum B, Rue TC, et al. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Arch Intern Med 2008, 168:1867-1873. 10.1001/archinternmed.2008.2, 2701288, 18809813.
77. Giuffrida FM, Guedes AD, Rocco ER, et al. Heterogeneous behavior of lipids according to HbA1c levels undermines the plausibility of metabolic syndrome in type 1 diabetes: data from a nationwide multicenter survey. Cardiovasc Diabetol 2012, 11:156. 10.1186/1475-2840-11-156, 3547761, 23270560.
78. Prince CT, Secrest AM, Mackey RH, et al. Pulse wave analysis and prevalent cardiovascular disease in type 1 diabetes. Atherosclerosis 2010, 213:469-474. 10.1016/j.atherosclerosis.2010.08.080, 2997940, 20880527.
79. Turkbey EB, Redheuil A, Backlund JY, et al. Aortic Distensibility in Type 1 Diabetes. Diabetes Care 2013, Epub ahead of print.
80. Genuth S, Backlund JY, Bayless M, et al. Effects of Prior Intensive versus Conventional Therapy and History of Glycemia on Cardiac Function in Type 1 Diabetes in the DCCT/EDIC. Diabetes 2013, Epub ahead of print.
81. Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003, 348:2294-2303. 2701300, 12788993.
82. Olson JC, Edmundowicz D, Becker DJ, Kuller LH, Orchard TJ. Coronary calcium in adults with type 1 diabetes: a stronger correlate of clinical coronary artery disease in men than in women. Diabetes 2000, 49:1571-1578. 10.2337/diabetes.49.9.1571, 10969842.
83. Snell-Bergeon JK, Hokanson JE, Jensen L, et al. Progression of coronary artery calcification in type 1 diabetes: the importance of glycemic control. Diabetes Care 2003, 26:2923-2928. 10.2337/diacare.26.10.2923, 14514603.
84. Thilo C, Standl E, Knez A, et al. Coronary calcification in long-term type 1 diabetic patients - a study with multi slice spiral computed tomography. Exp Clin Endocrinol Diabetes 2004, 112:561-565. 10.1055/s-2004-830418, 15578330.
85. Rathsman B, Rosfors S, Sjoholm A, Nystrom T. Early signs of atherosclerosis are associated with insulin resistance in non-obese adolescent and young adults with type 1 diabetes. Cardiovasc Diabetol 2012, 11:145. 10.1186/1475-2840-11-145, 3538551, 23185996.
86. Dalla Pozza R, Beyerlein A, Thilmany C, et al. The effect of cardiovascular risk factors on the longitudinal evolution of the carotid intima medial thickness in children with type 1 diabetes mellitus. Cardiovasc Diabetol 2011, 10:53. 10.1186/1475-2840-10-53, 3148557, 21679428.
87. Turek SJ, Hastings SM, Sun JK, King GL, Keenan HA. Sexual Dysfunction as a Marker of Cardiovascular Disease in Males With 50 or More Years of Type 1 Diabetes. Diabetes Care 2013, 36(10):3222-3226. 10.2337/dc13-0294, 23780949.
88. Pratte KA, Baron AE, Ogden LG, et al. Plasminogen activator inhibitor-1 is associated with coronary artery calcium in Type 1 diabetes. J Diabetes Complications 2009, 23:387-393. 10.1016/j.jdiacomp.2008.07.002, 18768333.
89. Bosnyak Z, Forrest KY, Maser RE, Becker D, Orchard TJ. Do plasminogen activator inhibitor (PAI-1) or tissue plasminogen activator PAI-1 complexes predict complications in Type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study. Diabet Med 2003, 20:147-151. 10.1046/j.1464-5491.2003.00898.x, 12581266.
90. American Diabetes Association (ADA) Standards of medical care in diabetes - 2013. Diabetes Care 2013, 36:S11-S66. American Diabetes Association (ADA).
91. Donaghue KC, Chiarelli F, Trotta D, Allgrove J, Dahl-Jorgensen K. Microvascular and macrovascular complications associated with diabetes in children and adolescents. Pediatr Diabetes 2009, 10(Suppl 12):195-203.
92. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010, 33:2285-2293. 10.2337/dc10-1303, 2945176, 20876709.
93. Geluk CA, Dikkers R, Kors JA, et al. Measurement of coronary calcium scores or exercise testing as initial screening tool in asymptomatic subjects with ST-T changes on the resting ECG: an evaluation study. BMC Cardiovasc Disord 2007, 7:19. 10.1186/1471-2261-7-19, 1959245, 17629903.
94. Budoff MJ, Gul KM. Expert review on coronary calcium. Vasc Health Risk Manag 2008, 4:315-324. 2496978, 18561507.
95. Donaghue KC, Fairchild JM, Craig ME, et al. Do all prepubertal years of diabetes duration contribute equally to diabetes complications?. Diabetes Care 2003, 26:1224-1229. 10.2337/diacare.26.4.1224, 12663601.
96. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr 1994, 125:177-188.
97. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
98. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000, 23(Suppl 2):B21-B29.
99. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000, 342:381-389. 2630213, 10666428.
100. Salardi S, Balsamo C, Zucchini S, et al. High rate of regression from micro-macroalbuminuria to normoalbuminuria in children and adolescents with type 1 diabetes treated or not with enalapril: the influence of HDL cholesterol. Diabetes Care 2011, 34:424-429. 10.2337/dc10-1177, 3024361, 21216861.
101. Amin R, Widmer B, Prevost AT, et al. Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ 2008, 336:697-701. 10.1136/bmj.39478.378241.BE, 2276285, 18349042.
102. Gorman D, Sochett E, Daneman D. The natural history of microalbuminuria in adolescents with type 1 diabetes. J Pediatr 1999, 134:333-337. 10.1016/S0022-3476(99)70459-2, 10064671.
103. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998, 105:1801-1815. 10.1016/S0161-6420(98)91020-X, 9787347.
104. Kubin M, Tossavainen P, Hannula V, et al. Prevalence of retinopathy in Finnish children and adolescents with type 1 diabetes: a cross-sectional population-based retrospective study. Arch Dis Child 2011, 96:963-968. 10.1136/adc.2011.210807, 21719439.
105. Barkai L, Kempler P, Vamosi I, et al. Peripheral sensory nerve dysfunction in children and adolescents with type 1 diabetes mellitus. Diabet Med 1998, 15:228-233. 10.1002/(SICI)1096-9136(199803)15:3<228::AID-DIA551>3.0.CO;2-8, 9545124.
106. Hyllienmark L, Brismar T, Ludvigsson J. Subclinical nerve dysfunction in children and adolescents with IDDM. Diabetologia 1995, 38:685-692. 10.1007/BF00401840, 7672490.
107. Lee SS, Han HS, Kim H. A 5-yr follow-up nerve conduction study for the detection of subclinical diabetic neuropathy in children with newly diagnosed insulin-dependent diabetes mellitus. Pediatr Diabetes 2010, 11:521-528. 10.1111/j.1399-5448.2009.00636.x, 20723100.
108. Riihimaa PH, Suominen K, Tolonen U, et al. Peripheral nerve function is increasingly impaired during puberty in adolescents with type 1 diabetes. Diabetes Care 2001, 24:1087-1092. 10.2337/diacare.24.6.1087, 11375375.
109. Solders G, Thalme B, Aguirre-Aquino M, et al. Nerve conduction and autonomic nerve function in diabetic children. A 10-year follow-up study. Acta Paediatr 1997, 86:361-366. 10.1111/j.1651-2227.1997.tb09023.x, 9174220.
110. Craig ME, Handelsman P, Donaghue KC, et al. Predictors of glycaemic control and hypoglycaemia in children and adolescents with type 1 diabetes from NSW and the ACT. Med J Aust 2002, 177:235-238.
111. Vanelli M, Chiarelli F, Chiari G, Tumini S. Relationship between metabolic control and quality of life in adolescents with type 1 diabetes. Report from two Italian centres for the management of diabetes in childhood. Acta Biomed 2003, 74(Suppl 1):13-17.
112. Holl RW, Swift PG, Mortensen HB, et al. Insulin injection regimens and metabolic control in an international survey of adolescents with type 1 diabetes over 3 years: results from the Hvidore study group. Eur J Pediatr 2003, 162:22-29. 10.1007/s00431-002-1037-2, 12486503.
113. Hari Kumar KV, Shaikh A, Prusty P. Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: A randomized, open label study. Diabetes Res Clin Pract 2013, doi: 10.1016/j.diabres.2013.1001.1020.
114. Ceriello A, Novials A, Ortega E, et al. Glucagon-Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes. Diabetes Care 2013, 36(8):2346-2350. 10.2337/dc12-2469, 23564922.
115. Klein R, Klein BE, Moss SE. The Wisconsin epidemiological study of diabetic retinopathy: a review. Diabetes Metab Rev 1989, 5:559-570. 10.1002/dmr.5610050703, 2689119.
116. van Hecke MV, Dekker JM, Stehouwer CD, et al. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study. Diabetes Care 2005, 28:1383-1389. 10.2337/diacare.28.6.1383, 15920056.
117. Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care 2002, 25:859-864. 10.2337/diacare.25.5.859, 11978681.
118. Wajchenberg BL, Feitosa AC, Rassi N, Lerario AC, Betti RT. Glycemia and cardiovascular disease in type 1 diabetes mellitus. Endocr Pract 2008, 14:912-923. 10.4158/EP.14.7.912, 18996824.
119. American Diabetes Association Hypertension Management in Adults With Diabetes. Diabetes Care 2004, 27:s65-s67. American Diabetes Association.
120. NICE. Hypertension The clinical management of primary hypertension in adults. NICE Clinical Guideline 127 2011, Available at http://publications.nice.org.uk/hypertension-cg127 [last accessed: 02-07-2013]. 2011, NICE. Hypertension.
121. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ 1996, 313:779-784. 10.1136/bmj.313.7060.779, 2352213, 8842069.
122. Cook J, Daneman D, Spino M, et al. Angiotensin converting enzyme inhibitor therapy to decrease microalbuminuria in normotensive children with insulin-dependent diabetes mellitus. J Pediatr 1990, 117:39-45. 10.1016/S0022-3476(05)82441-2, 2196359.
123. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004, 114:555-576.
124. Couper JJ, Staples AJ, Cocciolone R, et al. Relationship of smoking and albuminuria in children with insulin-dependent diabetes. Diabet Med 1994, 11:666-669. 10.1111/j.1464-5491.1994.tb00330.x, 7955992.
125. Astrup AS, Tarnow L, Rossing P, et al. Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. Kidney Int 2005, 68:1250-1257. 10.1111/j.1523-1755.2005.00521.x, 16105058.